ArticleCell death and differentiation2014
Interleukin-17 enhances immunosuppression by mesenchymal stem cells.
Article in Cell death and differentiation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 202 citations in OpenAlex.
- Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies.Cancers · 2026Review
- The Secretome Derived From Serum-Free Media of SHED-MSCs Can Modulate THP-1-Derived Macrophage Cells.Journal of cellular and molecular medicine · 2026Article
- In situ electrospinning at the operating table to immobilise mesenchymal stem cells on the bony wall for the regeneration of osteoporotic bone defects.Journal of nanobiotechnology · 2026Article
- Deteriorating fractional exhaled nitric oxide preceding pneumonitis during immune checkpoint inhibitor therapy: a case report.Respiratory medicine case reports · 2026Article
- Single-cell RNA sequencing identifies PD-L1 + mesenchymal stem cells with enhanced immunomodulatory capacity and alleviated the degree of ectopic new bone formation in ankylosing spondylitis.Stem cell research & therapy · 2025Article
- Innovative strategies to enhance MSCs efficacy in acute kidney injury (Review).International journal of molecular medicine · 2025Review
- PARP inhibition augments immunomodulatory function of mesenchymal stem/stromal cells by promoting STAT1 phosphorylation.Stem cell research & therapy · 2025Article
- The interrelationship between interleukin-17 A and the immunomodulation of mesenchymal stromal cells.Stem cell research & therapy · 2025Review
- Modulating Proliferation, Migration and Differentiation of Mesenchymal Stem Cells Using Interleukins.Current stem cell research & therapy · 2025Review
- Intracellular osteopontin potentiates the immunosuppressive activity of mesenchymal stromal cells.Stem cell research & therapy · 2024Article
- Species variations in muscle stem cell-mediated immunosuppression on T cells.Scientific reports · 2024Article
- Ultrasonic-assisted extraction of a low molecular weight polysaccharide from Nostoc commune Vaucher and its structural characterization and immunomodulatory activity.Ultrasonics sonochemistry · 2024Article
- Metformin rejuvenates Nap1l2-impaired immunomodulation of bone marrow mesenchymal stem cells via metabolic reprogramming.Cell proliferation · 2024Article
- Recent Advances of MSCs in Renal IRI: From Injury to Renal Fibrosis.Bioengineering (Basel, Switzerland) · 2024Review
- Fine Tuning Mesenchymal Stromal Cells - Code For Mitigating Kidney Diseases.Stem cell reviews and reports · 2024Review
- Combined Use of Tocilizumab and Mesenchymal Stem Cells Attenuate the Development of an Anti-HLA-A2.1 Antibody in a Highly Sensitized Mouse Model.International journal of molecular sciences · 2024Article
- Regulation of inflammation during wound healing: the function of mesenchymal stem cells and strategies for therapeutic enhancement.Frontiers in pharmacology · 2024Review
- Mesenchymal stem cells protect against sepsis-associated acute kidney injury by inducing Gal-9/Tim-3 to remodel immune homeostasis.Renal failure · 2023Article
- sFgl2 gene-modified MSCs regulate the differentiation of CD4Stem cell research & therapy · 2023Article
- Unraveling The Effects of DICER1 Overexpression on Immune-Related Genes Expression in Mesenchymal Stromal/Stem Cells: Insights for Therapeutic Applications.Cell journal · 2023Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-17 is one of the most potent and most actively investigated proinflammatory cytokines. In this study, we examined the effect of IL-17 on mesenchymal stem cells (MSCs) under the influence of inflammatory cytokines. Ironically, IL-17 dramatically enhanced the immunosuppressive effect of MSCs induced by IFNγ and TNFα, revealing a novel role of IL-17 in immunosuppression. Interestingly, we found that this action of IL-17 was dependent on the promoted expression of a key immune suppressive molecule, inducible nitric oxide synthase (iNOS), in MSCs. In a concanavalin A (ConA)-induced hepatitis mouse model, we found that IL-17 also enhanced the in vivo immunosuppressive effect of MSCs in an iNOS-dependent manner. Moreover, this promoting effect of IL-17 was found to be exerted through enhancing mRNA stability by modulating the protein level of ARE/poly(U)-binding/degradation factor 1 (AUF1), a well-known factor that promotes mRNA decay. In auf1(-/-) MSCs, IFNγ and TNFα could induce maximal immunosuppressive effect, both in vitro and in vivo, without the need for IL-17. Thus, our studies demonstrated that in the presence of MSCs, IL-17 promotes immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.